RhumbLine Advisers’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-16,228
| Closed | -$298K | – | 3046 |
|
|
2020
Q4 | $298K | Buy |
16,228
+498
| +3% | +$9.15K | ﹤0.01% | 2668 |
|
|
2020
Q3 | $288K | Sell |
15,730
-2,179
| -12% | -$39.9K | ﹤0.01% | 2539 |
|
|
2020
Q2 | $268K | Buy |
17,909
+174
| +1% | +$2.6K | ﹤0.01% | 2631 |
|
|
2020
Q1 | $281K | Buy |
17,735
+786
| +5% | +$12.5K | ﹤0.01% | 2439 |
|
|
2019
Q4 | $275K | Buy |
16,949
+490
| +3% | +$7.95K | ﹤0.01% | 2637 |
|
|
2019
Q3 | $245K | Sell |
16,459
-595
| -3% | -$8.86K | ﹤0.01% | 2674 |
|
|
2019
Q2 | $282K | Buy |
17,054
+2,056
| +14% | +$34K | ﹤0.01% | 2632 |
|
|
2019
Q1 | $259K | Sell |
14,998
-379
| -2% | -$6.55K | ﹤0.01% | 2618 |
|
|
2018
Q4 | $272K | Buy |
15,377
+5,074
| +49% | +$89.8K | ﹤0.01% | 2592 |
|
|
2018
Q3 | $187K | Sell |
10,303
-347
| -3% | -$6.3K | ﹤0.01% | 2749 |
|
|
2018
Q2 | $208K | Buy |
+10,650
| New | +$208K | ﹤0.01% | 2719 |
|
|
2017
Q2 | – | Sell |
-12,601
| Closed | -$149K | – | 2979 |
|
|
2017
Q1 | $149K | Buy |
12,601
+568
| +5% | +$6.72K | ﹤0.01% | 2723 |
|
|
2016
Q4 | $158K | Sell |
12,033
-2,581
| -18% | -$33.9K | ﹤0.01% | 2728 |
|
|
2016
Q3 | $212K | Buy |
14,614
+220
| +2% | +$3.19K | ﹤0.01% | 2651 |
|
|
2016
Q2 | $173K | Buy |
+14,394
| New | +$173K | ﹤0.01% | 2804 |
|
|
2016
Q1 | – | Sell |
-9,307
| Closed | -$200K | – | 3001 |
|
|
2015
Q4 | $200K | Buy |
+9,307
| New | +$200K | ﹤0.01% | 2800 |
|
|
2015
Q3 | – | Sell |
-7,745
| Closed | -$291K | – | 3023 |
|
|
2015
Q2 | $291K | Buy |
+7,745
| New | +$291K | ﹤0.01% | 2678 |
|